Merrimack Pharma: Annual Report 2014 (Merrimack) - Mar 8, 2015 - Anticipated patent expiry for composition in US between 2029-2035; Anticipated patent expiry for method of use in US between 2029-2035; Anticipated patent expiry for diagnostics in US between 2029-2035; Anticipated patent expiry for a PCT application in 2033 and 2035; Anticipated patent expiry in EU and related jurisdictions between 2028-2033; Anticipated expiry of exclusively licensed patents for composition of matter in US, EU and ROW in 2023; Anticipated expiry of non-exclusively licensed patents in US, EU and Canada for composition of matter in 2016
Anticipated patent expiry • Oncology
|